Jiang Hao, Liu Kai-yan, Tong Chun-rong, Jiang Bin, Lu Dao-pei
Institute of Hematology, People's Hospital, Beijing University, Beijing 100044, China.
Zhonghua Nei Ke Za Zhi. 2005 Mar;44(3):198-201.
To evaluate the efficacy of chemotherapy in combination with autologous cytokine induced killer cells for the treatment of acute leukemia.
41 patients with acute leukemia were evaluated; complete remission was achieved in these patients for more than 6 months duration after chemotherapy. 19 patients who received autologous cytokine induced killer (CIK) cells followed by chemotherapy constituted a CIK group and 22 patients who received the same term of chemotherapy only constituted a control group. Preparation of CIK cells was as follows: Peripheral blood mononuclear cells from the patient were collected by using blood cell separator, then cultured in the medium containing monoclonal antibody against CD(3), interleukin-2 and interferon gamma for about 10 days, and finally infused back to the patient on the first day after chemotherapy. The programs of chemotherapy in the two groups were similar.
19 patients in the CIK group received a total of 52 courses of CIK cells. 8 patients received 4 courses, 2 patients 3 courses, 5 patients 2 courses and 4 patients one course of treatment. The numbers of transfused CIK cells per patient were (14.2 +/- 8.5) x 10(9)/L; (2.2 approximately 30.0) x 10(9)/L (Mean +/- s; range) in one course of treatment. Continuous complete remission (CCR) rate was 73.4% in the CIK group versus 27.3% in the control group in a follow up of 4 years (P < 0.005). ALL patients who received >or= 3 courses of treatment in the CIK group have remained in CCR till the time of this study; the median time of CCR were 43 months (23 - 52 months). 4 of the 9 patients who received < 3 courses of CIK treatment relapsed after CR by 43, 17, 13 and 9 months respectively.
CCR rate was higher in patients with chemotherapy plus CIK cells for acute leukemia than in patients with chemotherapy alone. In the CIK group; the efficacy of therapy patients who received >or= 3 courses of treatment was better than that in patients who received < 3 courses of treatment.
评估化疗联合自体细胞因子诱导的杀伤细胞治疗急性白血病的疗效。
对41例急性白血病患者进行评估；这些患者在化疗后完全缓解持续时间超过6个月。19例接受自体细胞因子诱导的杀伤（CIK）细胞治疗后再进行化疗的患者组成CIK组，22例仅接受同期化疗的患者组成对照组。CIK细胞的制备如下：使用血细胞分离机采集患者外周血单个核细胞，然后在含有抗CD(3)单克隆抗体、白细胞介素-2和干扰素γ的培养基中培养约10天，最后在化疗后第一天回输至患者体内。两组的化疗方案相似。
CIK组19例患者共接受52个疗程的CIK细胞治疗。8例患者接受4个疗程，2例患者接受3个疗程，5例患者接受2个疗程，4例患者接受1个疗程的治疗。每个患者每次治疗输注的CIK细胞数量为(14.2±8.5)×10⁹/L；(2.2至30.0)×10⁹/L（平均值±标准差；范围）。在4年的随访中，CIK组的持续完全缓解（CCR）率为73.4%，而对照组为27.3%（P<0.005）。CIK组中所有接受≥3个疗程治疗的患者直至本研究时仍处于CCR状态；CCR的中位时间为43个月（23至52个月）。9例接受<3个疗程CIK治疗的患者中有4例在CR后分别于43、17、13和9个月复发。
急性白血病患者化疗加CIK细胞治疗的CCR率高于单纯化疗患者。在CIK组中，接受≥3个疗程治疗的患者的治疗效果优于接受<3个疗程治疗的患者。
